Navigation Links
Aeolus Pharmaceuticals' AEOL 10113 Demonstrates Potential as a,Protector of Healthy Normal Cells from Cancer Radiation Therapy

LAGUNA NIGUEL, Calif.--(BUSINESS WIRE)--Apr 19, 2007 - Aeolus Pharmaceuticals, Inc. (OTCBB:AOLS) announced the presentation of data by researchers at Loma Linda University Medical Center, National Jewish Medical and Research Center and Duke University showing that one of the Company's metalloporphyrin antioxidants, AEOL 10113, demonstrated protection of healthy normal cells in mice with prostate tumor cells treated with radiation therapy. The study also showed that the compound did not interfere with the tumor destruction effects of the radiation therapy.

Researchers reported a statistically significant decrease in tumor growth in animals that received radiation alone (p less than 0.05, days 9, 11-14); and in animals that received radiation plus drug (p less than 0.05, days 11-15). Survival was improved in the radiation plus drug group as 15% of the mice survived (with tumor volumes of less than 2,000 cubic mm) 7 and 9 days longer compared to radiation only and drug only groups, respectively. The researchers concluded that the results demonstrate that AEOL 10113 did not protect tumor response to radiation and there were no drug-related toxicities detected. The data support further investigation of metalloporphyrin antioxidants as a normal tissue protectant during radiotherapy.

The Potential for Metalloporphyrin Antioxidants in Radiotherapy for Cancer

Radiotherapy treatment in cancer has the positive effect of tumor destruction, but also has the negative effect of normal tissue damage. Optimal dosing in radiotherapy balances maximum tumor destruction with minimal toxicity and damage to normal tissue. The "ionizing radiation" used in cancer radiotherapy generates reactive oxygen species (ROS) and other free radicals. These free radicals cause DNA damage and cell death. Catalytic antioxidants, such as Aeolus' AEOL 10150 and AEOL 10113 have been shown to neutralize free radicals and can reduce radiati
'"/>




Page: 1 2 3

Related medicine technology :

1. Study Demonstrating Aeolus Compounds Neuroprotection in Parkinsons Disease Published in the Journal of Neuroscience
2. Aeolus Pharmaceuticals AEOL 10113 May Play an Important Role Regulating the Oxidative Damage Induced by Ionizing Radiation
3. Aeolus Pharmaceuticals AEOL 10150 Highlighted in Nature Genetics Publication
4. Aeolus Pharmaceuticals Announces Successful Completion of Multiple Dose Safety Study of AEOL 10150
5. Faust Pharmaceuticals Phase IIa Results for Parkinsons Disease Presented at International Congress of Parkinsons Disease and Movement Disorders
6. Data from Rexahn Pharmaceuticals Phase I Trial of RX-0201 (Archexin) to Be Presented at the 43rd American Society of Clinical Oncology Annual Meeting in Chicago
7. VGX Pharmaceuticals Novel HIV and Pandemic Influenza DNA Vaccine Candidates Trigger Robust Immune Responses and Protection in Pre-Clinical Models
8. ACADIA Pharmaceuticals Schizophrenia Programs to Be Presented at the 2007 International Congress on Schizophrenia Research
9. The International Myeloma Foundation Says Data Reported at a Global Medical Meeting in Greece Demonstrates Improved Survival for a Wide Range of Myeloma Patients
10. Publication on Pixantrone Preclinical Studies Demonstrates Reduced Cardiotoxicity Compared to Equiactive Doses of Doxorubicin and Mitoxantrone
11. New Research Demonstrates Broad Efficacy of Azixa (MPC-6827) Against Multiple Tumor Types and in Drug Resistant Cell Lines
Post Your Comments:
(Date:7/31/2014)...  Cepheid (NASDAQ: CPHD ) today announced that ... invited investors to participate via webcast. ... NY Wednesday, August 13, 2014 at 9.10 a.m. ... New York, NY Thursday, September 4, 2014 ... Webcasts To access the live webcasts for these events, please ...
(Date:7/31/2014)... , July 31, 2014 Rock Creek ... that it has initiated the development of its lead ... and that it has selected Quotient Clinical, The Translational ... (UK) to run its early development programs. ... Trial Application (CTA) by the end of the third ...
(Date:7/31/2014)... , July 31, 2014 Lazarus Effect, a ... interventional devices to facilitate removal of blood clots, announced ... the financing will support EU commercialization of several approved ... the Lazarus ReCover™ and Lazarus Cover™ in ... reflects investor confidence in the value of our novel, ...
Breaking Medicine Technology:Cepheid to Webcast Upcoming Financial Presentations 2Rock Creek Pharmaceuticals Provides Update of its European Drug Development Regulatory Strategy and selects Quotient Clinical for its early development programs 2Rock Creek Pharmaceuticals Provides Update of its European Drug Development Regulatory Strategy and selects Quotient Clinical for its early development programs 3Rock Creek Pharmaceuticals Provides Update of its European Drug Development Regulatory Strategy and selects Quotient Clinical for its early development programs 4Lazarus Effect Closes $5 Million Financing 2
... SAN DIEGO, Jan. 31 TargeGen, Inc. ... multi-center Phase I/II clinical trial of,TG101348, an ... JAK2 in,patients with myeloproliferative diseases., (Logo: ... of JAK2 is implicated in the pathogenesis ...
... Mayo clinic in key role in treatment discovery, ... New York,based company Cytopia Limited (ASX: CYT) announced ... demonstrated potent activity in cells,isolated from patients with ... of diseases where there is over-production of,particular cells ...
Cached Medicine Technology:TargeGen Announces Initiation of Clinical Trial of JAK2 Inhibitor TG101348 in Myeloproliferative Disease Patients 2JAK2 Inhibitor Shows Potent Activity in Cells From MPD Patients 2
(Date:8/1/2014)... 01, 2014 The North America Sports Drink ... North America, with analysis and forecast of revenue. The Sports ... around $5,021.9 million in 2012 to $6,243 million by 2018, ... Browse through the TOC of the North America Sports Drink ... provided. This also provides a glimpse of the segmentation in ...
(Date:8/1/2014)... Society of America (GSA) the nation,s largest ... has chosen Sean P. Curran, PhD, of the University ... Nathan Shock New Investigator Award. , This distinguished honor ... aging through basic biological research. It was established in ... of GSA and pioneer in gerontological research at the ...
(Date:8/1/2014)... of electronic reminders such as text messages, emails or ... adhere to a preadmission antiseptic showering regimen known to ... to a first-of-its-kind study published in the August issue ... Surgeons . , Each year approximately 400,000 SSIs occur ... according to data sources cited by study authors. ...
(Date:8/1/2014)... (PRWEB) August 01, 2014 Chilton ... portal that aims to empower patients and their ... their health care by providing easy, secure access ... gives patients instant, web-based access to their health ... radiology results, medications, allergies, demographic information, visit history, ...
(Date:8/1/2014)... NY (PRWEB) August 01, 2014 Ticket Down ... at Maple Lane Farms in Knoxville/Greenback, TN; Ingram Farms ... Whitehurst Cattle Farm in Archer/Gainesville, FL. Luke Bryan is currently ... with Lee Brice and Cole Swindell. Bryan is responsible for ... world each summer and this year, just because the summer ...
Breaking Medicine News(10 mins):Health News:North America Sports Drinks Market is Expected to Reach $6,243 Million in 2018 - New Report by MicroMarket Monitor 2Health News:North America Sports Drinks Market is Expected to Reach $6,243 Million in 2018 - New Report by MicroMarket Monitor 3Health News:North America Sports Drinks Market is Expected to Reach $6,243 Million in 2018 - New Report by MicroMarket Monitor 4Health News:Curran to receive GSA's 2014 Nathan Shock New Investigator Award 2Health News:Electronic reminders can help patients prevent surgical site infections 2Health News:Electronic reminders can help patients prevent surgical site infections 3Health News:Chilton Medical Center Launches Online Patient Portal 2Health News:Luke Bryan Tickets at Maple Lane Farms in Knoxville, Ingram Farms in Auburn, Cross Creek Place in Tallahassee & Whitehurst Cattle Farm in Gainesville Now Available 2Health News:Luke Bryan Tickets at Maple Lane Farms in Knoxville, Ingram Farms in Auburn, Cross Creek Place in Tallahassee & Whitehurst Cattle Farm in Gainesville Now Available 3Health News:Luke Bryan Tickets at Maple Lane Farms in Knoxville, Ingram Farms in Auburn, Cross Creek Place in Tallahassee & Whitehurst Cattle Farm in Gainesville Now Available 4
... Eliminates Need for Cadavers and Accelerates Physician TrainingGREAT ... maker of anatomically accurate surgical training models, is ... new Maxillary Clinical Sinus Trainer. This innovative ... to train ENT surgeons on their new FinESS(TM) ...
... is a Gift that Helps Doctors Improve Health CareWINSTON-SALEM, N.C., ... 30th, DrScore.com , the physician rating Web ... feedback by rating their doctors online. "The best gift patients ... in general is honest, constructive feedback," says Steve Feldman M.D., ...
... in French . , Montreal, March ... to reality, thanks to a discovery from scientists at ... According to a study published in the journal ... first to clone, produce and purify a protein important ...
... incisionless, non-invasive procedure treats patients with chronic reflux ... Center today announced that two surgeons from its ... Washington State on Monday, March 16. EsophyX ... gastroesophageal reflux disease, or GERD. The two ...
... What can you buy with a dollar anymore? ... and treatment for those who cannot afford to battle breast ... Brandon Mendelson and the 1 in 8 Foundation are challenging ... $1 and provide care and complete support for women and ...
... on factory farmsWASHINGTON, March 17 Nearly one year ... released its landmark recommendations on how America should reform ... Slaughter today introduced the Preservation of Antibiotics for Medical ... the Federal Food, Drug, and Cosmetic Act to withdraw ...
Cached Medicine News:Health News:Chamberlain Group Surgical Training Model Facilitates New Treatment for Chronic Rhinosinusitis 2Health News:Chamberlain Group Surgical Training Model Facilitates New Treatment for Chronic Rhinosinusitis 3Health News:Rate Your Doctor at DrScore.com for Doctor's Day 2Health News:Rate Your Doctor at DrScore.com for Doctor's Day 3Health News:Researchers clone key sperm-binding proteins 2Health News:Northwest Hospital Surgeons Perform First EsophyX Procedure in Washington State 2Health News:$1 Can Make The Difference 2Health News:Pew Applauds Introduction of Preservation of Antibiotics for Medical Treatment Act 2Health News:Pew Applauds Introduction of Preservation of Antibiotics for Medical Treatment Act 3Health News:Pew Applauds Introduction of Preservation of Antibiotics for Medical Treatment Act 4
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: